A Phase 1 Dose Escalation and Expansion Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, for the Treatment of Metastatic Uveal Melanoma

Sapna P. Patel,1 Meredith McKeen,2 Sophie Piperno-Neumann,2 Alexander N. Shoushtari,3 Leonel Hernandez-Ayerza,4 Mariela Orofi,5 Shaheer Khan,6 Kamehan Montazeri,1 Ellen Kapilstein6, Elizabeth Buchbinder7, Samuel Agresta8, Sarah Reilly9, Katrina Patiquin6, Dennis Hickman,2 Murphy Hentemann,2 Dillon Corrigan,2 Jessica Piel,2 Lindsey Granlund,2 Paul Martin4, Inderjit Mehmi5

The University of Texas MD Anderson Cancer Center, Houston, TX; 2Sarah Cannon Research Institute, Nashville, TN; 3University of California, San Francisco, San Francisco, CA; 4Tulane University, New Orleans, LA; 5University of Kentucky, Lexington, KY; 6Memorial Sloan Kettering Cancer Center, New York, NY; 7Icahn School of Medicine at Mount Sinai, New York, NY; 8University of Florida, Jacksonville, FL; 9Thomas Jefferson University, Icahn School of Medicine, Philadelphia, PA; 10Columbia University Medical Center, New York, NY; 11Weill医学院; 12University of Texas Southwestern Medical Center, Dallas, TX; 13Baylor College of Medicine, Houston, TX; 14University of California, Los Angeles, CA; 15University of California, San Francisco, San Francisco, CA; 16University of Michigan, Ann Arbor, MI; 17Seagen, Seattle, WA; 18Syntrix Bio, San Francisco, CA; 19TriSalus Life Sciences, St. Louis, MO; 20Advance Knowledge in Health, LLC, New York, NY; 21Bayside Medical Group, New York, NY; 22Walgreens Health, Inc., Lake Forest, IL; 23Foghorn Therapeutics Inc., Cambridge, MA; 24Foghorn Therapeutics Inc., Cambridge, MA; 25Committee for Research and Treatment of Cancer, Dallas, TX; 26American Society of Clinical Oncology, Chicago, IL; 27American Society of Clinical Oncology, Chicago, IL

Plasma Pharmacokinetics: Mean Precise PK Profiles

• FHD-286 exposure increases with dose between 2.5 mg QD and 10 mg QD and accumulates with QD dosing, steadily state typically reached by 2 weeks.
• FHD-286 half-life is ~24 hours.

Baseline Demographics and Disease Characteristics

BAPF complexes are critical to the regulation of cellular
chromatin remodeling complexes known as BAF, which are
comprised of two subfamilies: BAF155/BAF170 and BAF200/BAF250.

BAF complexes are critical to the regulation of cellular
chromatin remodeling complexes known as BAF, which are
comprised of two subfamilies: BAF155/BAF170 and BAF200/BAF250.

FHD-286 is a potent, selective, allosteric, and orally
bioavailable small-molecule inhibitor of the enzymatic
activity of BRG1/BRM (SMARCA4/SMARCA2).

FHD-286 is a potent, selective, allosteric, and orally
bioavailable small-molecule inhibitor of the enzymatic
activity of BRG1/BRM (SMARCA4/SMARCA2).

Baseline Demographics and Disease Characteristics

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

• FHD-286 is a first-in-class, orally administered compound that potently and selectively inhibits the ATPase components of the BAF complex.

• FHD-286 is a first-in-class, orally administered compound that potently and selectively inhibits the ATPase components of the BAF complex.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

• FHD-286 is a potent, selective, allosteric, and orally
bioavailable small-molecule inhibitor of the enzymatic
activity of BRG1/BRM (SMARCA4/SMARCA2).

• FHD-286 is a potent, selective, allosteric, and orally
bioavailable small-molecule inhibitor of the enzymatic
activity of BRG1/BRM (SMARCA4/SMARCA2).

Baseline Demographics and Disease Characteristics

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.

Efficacy: Tumor Response

Subjects With Measurable Tumor Burden

Subjects With Measurable Tumor Burden

Baseline characteristics were generally well-balanced across all arms.